Monograph Title | Section | Source Publication | Page Number Sort descending | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
<191> IDENTIFICATION TESTS—GENERAL | CHEMICAL IDENTIFICATION TESTS/Thiosulfate | Second Supplement to USP40–NF35 | Online | 17-Nov-2017 | 1-Dec-2017 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 1 of A.: Change yellow; with the addition of sulfur dioxide, filter paper moistened with mercurous nitrate TS blackens. to: yellow, and evolve sulfur dioxide, which blackens filter paper moistened with mercurous nitrate TS. |
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Revision Bulletin (Official August 01, 2018) | Online | 30-Aug-2019 | 1-Sep-2019 | NA | NA | In USP Fexofenadine Related Compound A RS: Change Benzeneacetic acid, 4-[1-oxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-α,α-dimethyl. to: 2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid; Also known as Benzeneacetic… Read More |
EPINEPHRINE | ADDITIONAL REQUIREMENTS | USP43–NF38 | Online | 24-Apr-2020 | 1-May-2020 | NA | NA | This erratum applies to the USP-NF ONLINE platform only. In USP Reference Standards <11>: Add USP Racepinephrine Hydrochloride RS |
ENSULIZOLE | IDENTIFICATION | USPNF Online | Online | 29-Mar-2024 | 1-Apr-2024 | NA | NA | In B.: Change The retention time of the major peak of the Sample solution exhibits maxima and minima at the same wavelengths as those of the Standard solution, as obtained in the Assay. to: The retention time of the major… Read More |
<659> PACKAGING AND STORAGE REQUIREMENTS | GENERAL DEFINITIONS/Packaging Definitions | Second Supplement to USP43–NF38 | Online | 26-Mar-2021 | 1-Dec-2025 | NA | NA | In Light-resistant container: Change 〈661.2〉, Functionality, Spectral Transmission Requirements for Light-Resistant Components and Systems. to: 〈661.2〉, Functionality Test Method, Spectral Transmission Requirements for Light-… Read More |
GADOTERATE MEGLUMINE INJECTION | OTHER COMPONENTS/Content of Meglumine | USPNF 2021 ISSUE 1 | Online | 28-May-2021 | 1-Jun-2021 | NA | NA | In Analysis: Change Result = (a/α) × (1/l) × (1/L) × 100 to: Result = (a/α) × 100 × (1/l) × (1/L) × 100 |
DICLOFENAC POTASSIUM | IDENTIFICATION/C. | USPNF 2021 ISSUE 1 | Online | 27-Aug-2021 | 1-Sep-2021 | NA | NA | In Sample solution: Change 7 N hydrochloride acid to: 7 N hydrochloric acid |
DACARBAZINE FOR INJECTION | IMPURITIES/Organic Impurities | USPNF 2021 ISSUE 1 | Online | 19-Nov-2021 | 1-Dec-2021 | NA | NA | Delete Diluent: 4.0 mg/mL of citric acid in water |
SORAFENIB TABLETS | PERFORMANCE TESTS/Dissolution <711> | USPNF Online | Online | 28-Jan-2022 | 1-Feb-2022 | NA | NA | In Tolerances: Change NLT 75 (Q) of the labeled amount of sorafenib (C21H16ClF3N4O3) is dissolved. to: NLT 75% (Q) of the labeled amount of sorafenib (C21H16… Read More |
FLUOCINOLONE ACETONIDE | Organic Impurities | USPNF Online | Online | 27-May-2022 | 1-Jun-2022 | NA | NA | In Acceptance criteria/Total impurities: Change NMT 2.5%. Disregard any peak below 0.05% of the peak area of fluocinolone acetonide from the Standard solution. to: NMT 2.5%. Disregard any peak below 0.05% of the peak area of… Read More |
TRYPTOPHAN | ADDITIONAL REQUIREMENTS/USP Reference Standards 〈11〉 | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In USP Tryptophan Related Compound A RS: Change 3,3′-[Ethylidenebis(1H-indole-1,3-diyl)]bis[2S)-2-aminopropanoic]acid. C24H26N4O4 432.49 to: (2S,2'S)-3,3'-[Ethane-1,1-diylbis(1H-… Read More |
TETRACYCLINE HYDROCHLORIDE | SPECIFIC TESTS/Bacterial Endotoxins Test <85> | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | Change Where the label states tetracycline hydrochloride must be subjected to further processing during the preparation of injectable dosage forms, the level of bacterial endotoxins are such that the requirement under the relevant dosage form monograph(s) in… Read More |
MESO-ZEAXANTHIN PREPARATION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 27-Jan-2023 | 1-Feb-2023 | NA | NA | In USP meso-Zeaxanthin RS: Change (3R,3′S-meso)-Zeaxanthin. to: (3R,3′S)-Zeaxanthin. |
DEXTRATES | ASSAY/Dextrose Equivalent | USPNF Online | Online | 31-Mar-2023 | 1-May-2023 | NA | NA | In Analysis: Change rA = peak response of each saccharide degree of polymerization (DP1–DP3) in the Sample solution (If any peaks of DP4 and above are observed in the sample, take the summation… Read More |
ATORVASTATIN CALCIUM | ADDITIONAL REQUIREMENTS/USP Reference Standards 〈11〉 | USPNF Online | Online | 26-May-2023 | 1-Jun-2023 | NA | NA | Change USP Atorvastatin Related Compound H RS (lactone impurity) to: USP Atorvastatin Related Compound H RS Also known as Lactone impurity; AND Change USP Atorvastatin Related Compound I RS (acetonide impurity) to: USP Atorvastatin Related… Read More |
CRANBERRY FRUIT DRY JUICE | IDENTIFICATION | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In A./Standard solution B: Change USP Procyanidin A2 RS to: USP Procyanidin A2 RS AND In A./System suitability/Suitability requirements/Derivatization reagent B/White light… Read More |
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CAPSULES | PERFORMANCE TESTS | USPNF Online | Online | 17-Nov-2023 | 1-Dec-2023 | NA | NA | In Dissolution 〈711〉/Test for dutasteride/Tier 2/Medium: Change 10 g/L of cetyltrimethylammonium bromide and 750,000 USP units of activity/mg of pepsin, purified in 0.1 N hydrochloric acid; 900 mL to: Dissolve 10 g of… Read More |
Olanzapine Tablets | ASSAY/Procedure | Revision Bulletin (Official July 01, 2012) | Online | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 10 of Analysis: Change CU = concentration of olanzapine in the Sample solution (mg/mL) to: CU = nominal concentration of olanzapine in the Sample solution (mg/mL) |
CHLORPHENIRAMINE MALEATE | SPECIFIC TESTS/Optical Rotation, Specific Rotation <781> | Second Supplement to USP38–NF33 | Online | 25-Sep-2015 | 1-Oct-2015 | USP40–NF35 | First Supplement to USP39–NF34 | Line 1: Delete Specific Rotation |
ALMOTRIPTAN TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | Revision Bulletin (Official February 01, 2017) | Online | 31-Mar-2017 | 1-Apr-2017 | USP41–NF36 | USP41–NF36 | Line 4 of USP Almotriptan Related Compound B RS: Change ½C4H4O to: ½C4H4O4 |
PAROXETINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | First Supplement to USP40–NF35 | Online | 23-Feb-2018 | 1-Mar-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 1 of USP Paroxetine Related Compound F RS: Change trans(−)-1-Methyl-3-[1,3-benzodioxol-5-yloxy)methyl]-4-(fluorophenyl)piperidine. to: (3S,4R)-3-[(Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methylpiperidine. |
TRANYLCYPROMINE TABLETS | PERFORMANCE TESTS/Dissolution <711> | First Supplement to USP41–NF36 | Online | 28-Sep-2018 | 1-Oct-2018 | USP43–NF38 | Second Supplement to USP41–NF36 | This erratum applies to the new USP-NF ONLINE platform only. Change System suitability ▲▲1S (USP41) Sample: Standard solution Suitability requirements Tailing factor… Read More |
LEVALBUTEROL INHALATION SOLUTION | IMPURITIES/Limit of S-Albuterol | USP42–NF37 | Online | 26-Apr-2019 | 1-May-2019 | NA | NA | In Mobile phase: Change ▲Acetonitrile, methanol, and acetic acid (50:50). To each liter of the solution add 3 mL of acetic acid and 1 mL of triethylamine.▲ (USP 1-May-2019) to: Acetonitrile and methanol (50:50… Read More |
CARVEDILOL | ADDITIONAL REQUIREMENTS/USP Reference Standards | USP43–NF38 | Online | 18-Dec-2020 | 1-Jan-2021 | NA | NA | In USP Carvedilol Related Compound A RS: Change 629.74 to: 629.75 AND In USP Carvedilol Related Compound B RS: Change 645.74 to: 645.76 AND In USP Carvedilol Related Compound C RS: Change 496.60 to: 496.61 AND In USP… Read More |
MIRTAZAPINE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP43–NF38 | Online | 26-Mar-2021 | 1-Apr-2021 | NA | NA | In USP Mirtazapine Resolution Mixture RS: Change Impurity D: 1,2,3,4,10,14b-Hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine. to: Impurity D: [Note–This impurity may be available either as the free base form or as the hydrochloride salt… Read More |
QUETIAPINE EXTENDED-RELEASE TABLETS | ASSAY/Procedure/System Suitability | USPNF 2021 ISSUE 1 | Online | 27-Aug-2021 | 1-Sep-2021 | NA | NA | In Resolution: Change NLT 2.0 between the quetiapine desthoxy and quetiapine peaks; System suitability solution to: NLT 2.0 between the quetiapine desethoxy and quetiapine peaks; System suitability solution |
SUCCINYLCHOLINE CHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF 2021 ISSUE 1 | Online | 31-Dec-2021 | 1-Jan-2022 | NA | NA | In USP Succinylmonocholine Chloride RS: Change Ethanaminium, 2-(carboxy-1-oxopropoxy)-N,N,N-trimethyl-, chloride. to: Ethanaminium, 2-(3-carboxy-1-oxopropoxy)-N,N,N-trimethyl-, chloride; Also… Read More |
PANTOPRAZOLE SODIUM | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 25-Mar-2022 | 1-Apr-2022 | NA | NA | In USP Pantoprazole Related Compound E RS: Change A mixture of the stereoisomers of 6,6′-bis(difluoromethoxy)-2,2′-bis[[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl]-1H,1′H-5,5′-bibenzimidazolyl. to: 6,6′-Bis(difluoromethoxy)-2,2′-bis[[(3,4-… Read More |
ATRACURIUM BESYLATE | CHEMICAL INFORMATION | USPNF Online | Online | 27-May-2022 | 1-Jun-2022 | NA | NA | Change 2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimeth oxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester to: 2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate,… Read More |
IRINOTECAN HYDROCHLORIDE INJECTION | DEFINITION | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | NA | Change NTL 90.0% and NMT 110.0% to: NLT 90.0% and NMT 110.0% |
DOXAZOSIN MESYLATE | IMPURITIES/Organic Impurities | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | In Analysis: Change CS = concentration of the corresponding USP Doxazosin Related Compound RS or USP Doxazosin Mesylate RS (for calculating unspecified impurities) in the Standard solution (mg/mL) to: CS… Read More |
ISOBUTYL ALCOHOL | ASSAY/Procedure | USPNF Online | Online | 27-Jan-2023 | 1-Feb-2023 | NA | NA | In Analysis: Change rS = sum of all the peaks except those each of which with an area less than 0.1 times the area of the major peak from the Reference solution to: rT = sum of all the peaks except those… Read More |
RISEDRONATE SODIUM DELAYED-RELEASE TABLETS | ASSAY | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | Delete [Note—Use a non-metallic liquid chromatography system for analysis.] |
ATORVASTATIN CALCIUM TABLETS | IMPURITIES/Organic Impurities | USPNF Online | Online | 30-Jun-2023 | 1-Jul-2023 | NA | NA | In Analysis: Change Mr1 = molecular weight of atorvastatin, 558.64 Mr2 = molecular weight of atorvastatin calcium, 1155.34 to: Mr1 = molecular weight of atorvastatin, 558.65 M… Read More |
AZITHROMYCIN | ADDITIONAL REQUIREMENTS | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In USP Reference Standards 〈11〉/USP Azaerythromycin A RS: Change 734.96 to: 734.97 AND In USP Azithromycin Related Compound F RS: Change 762.97 to: 762.98 AND In USP Desosaminylazithromycin RS: Change 590.79 to: 590.80 |
<81> ANTIBIOTICS—MICROBIAL ASSAYS | APPENDICES | USPNF Online | Online | 29-Dec-2023 | 1-Jan-2024 | NA | NA | In two instances in Appendix 1 equations: Change 14.020 to: 14.022 |
ONDANSETRON INJECTION | Assay | Second Supplement to USP36–NF31 | Online | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 7 of Procedure: Change (293.36 / 329.82)(25C / V)(rU / rS) to: (293.36 / 329.83)(25C / V)(rU / rS) AND Line 8 of Procedure: Change 329.82 to: 329.83 |
FERRIC AMMONIUM CITRATE | Mercury | Second Supplement to USP37–NF32 | Online | 27-Mar-2015 | 1-Apr-2015 | USP39–NF34 | USP39–NF34 | Line 1 of Procedure: Change Add 5 mL of stannous chloride solution (1 in 10) to each solution to: Add 5 mL of Stannous Chloride Solution to each solution |
<210> MONOSACCHARIDE ANALYSIS | PROCEDURES/Procedure 3: Enzymatic Hydrolysis and Analysis by RP-HPLC of DMB-labeled Sialic Acids | First Supplement to USP41–NF36 | Online | 25-May-2018 | 1-Jun-2018 | USP42–NF37 | Second Supplement to USP41–NF36 | Line 6 of Analysis: Change Convert the protein concentration from mg/mL to (1 μM = 1 nmol/mL). to: Convert the protein concentration from mg/mL to μM (1 μM = 1 nmol/mL). |
LIDOCAINE | ASSAY/Procedure | First Supplement to USP41–NF36 | Online | 30-Nov-2018 | 1-Dec-2018 | USP43–NF38 | USP42–NF37 | This erratum applies to the new USP-NF ONLINE platform only. Line 2 of Standard solution: Change 1 N sodium hydroxide, to: 1 N hydrochloric acid, AND Line 2 of Sample solution: Change 1 N sodium hydroxide, to: 1 N… Read More |
PACLITAXEL INJECTION | TITLE | USPNF 2021 ISSUE 1 | Online | 26-Feb-2021 | 1-May-2021 | NA | NA | Change Paclit 1axel Injection to: Paclitaxel Injection |
TIAGABINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF 2021 ISSUE 1 | Online | 29-Oct-2021 | 1-Nov-2021 | NA | NA | In USP Tiagabine Hydrochloride RS: Delete [NOTE—Available in monohydrate form.] |
ONDANSETRON HYDROCHLORIDE | USP Reference standards <11> | USPNF Online | Online | 28-Jan-2022 | 1-Feb-2022 | NA | NA | In USP Ondansetron Related Compound A RS: Change 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride. to: 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4H-carbazol-4-one hydrochloride. AND… Read More |
DACARBAZINE FOR INJECTION | IMPURITIES | USPNF Online | Online | 29-Apr-2022 | 1-May-2022 | NA | NA | Delete Limit of 2-Azahypoxanthine test |
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE TABLETS | ASSAY/Procedure | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | In Buffer: Change Adjust with phosphoric acid to a pH of 6.4 ± 0.01. to: Adjust with phosphoric acid to a pH of 6.4 ± 0.1. |
SODIUM PICOSULFATE | IMPURITIES/Organic Impurities | USPNF Online | Online | 30-Sep-2022 | 1-Oct-2022 | NA | NA | In Buffer: Change cetylrimethylammonium bromide, to: cetyltrimethylammonium bromide, |
MOMETASONE FUROATE TOPICAL SOLUTION | IDENTIFICATION | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | NA | In test A: Change The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, both relative to the internal standard, as obtained in the Assay. to: The retention time of the major… Read More |
MIRTAZAPINE TABLETS | IMPURITIES/Organic Impurities | USPNF Online | Online | 24-Feb-2023 | 1-Mar-2023 | NA | NA | In System suitability/Suitability requirements/Resolution: Change 10-ketomirtazpine to: 10-ketomirtazapine AND In Table 1: Change 1-Ketomirtazpinec to: 1-Ketomirtazapinec |
VIGABATRIN TABLETS | IMPURITIES/Organic Impurities | USPNF Online | Online | 28-Apr-2023 | 1-May-2023 | NA | NA | In Analysis: Change CS = concentration of USP Vigabatrin Related Compound A in the Standard solution to: CS = concentration of USP Vigabatrin Related Compound A RS in the Standard solution |
AZITHROMYCIN FOR INJECTION | ADDITIONAL REQUIREMENTS | USPNF Online | Online | 28-Jul-2023 | 1-Aug-2023 | NA | USPNF 2024 Issue 2 | In USP Reference Standards 〈11〉/USP Azaerythromycin A RS: Change 734.96 to: 734.97 AND In USP Azithromycin N-oxide RS: Change 764.98 to: 765.00 AND In USP N-Demethylazithromycin RS: Change 734.96 to: 734.97… Read More |